Regulus Therapeutics (RGLS)

May 27, 2025, 7:56 AM EDT - 9 days ago

Novartis announces commencement of tender offer to acquire Regulus Therapeutics

NVS

May 8, 2025, 4:05 PM EDT - 4 weeks ago

Regulus Therapeutics Reports First Quarter 2025 Financial Results and Recent Updates

May 4, 2025, 12:25 PM EDT - 4 weeks ago

REGULUS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Regulus Therapeutics Inc. - RGLS

Apr 30, 2025, 12:24 PM EDT - 5 weeks ago

Crude Oil Falls Over 3%; Regulus Therapeutics Shares Spike Higher

NVS

Apr 30, 2025, 11:22 AM EDT - 5 weeks ago

Novartis To Buy US Kidney Drug Developer Regulus Therapeutics For Around $800 Million

NVS

Apr 30, 2025, 7:50 AM EDT - 5 weeks ago

Novartis to Acquire Regulus in $1.7 Billion Deal

NVS

Apr 30, 2025, 7:25 AM EDT - 5 weeks ago

Novartis to buy Regulus Therapeutics for up to $1.7 billion

NVS

Apr 30, 2025, 7:10 AM EDT - 5 weeks ago

Novartis to acquire Regulus Therapeutics and farabursen, an investigational microRNA inhibitor to treat ADPKD, the most common genetic cause of renal failure

NVS

Apr 30, 2025, 7:00 AM EDT - 5 weeks ago

Regulus Therapeutics Enters into Agreement to be Acquired by Novartis AG

NVS

Apr 2, 2025, 8:00 AM EDT - 2 months ago

Regulus Therapeutics to Present at the 2025 Oppenheimer Innovation on the Island Biotech Summit

Mar 27, 2025, 12:59 PM EDT - 2 months ago

Regulus Therapeutics Stock Shoots Higher After Positive Results From Investigational Drug For Rare Type Of Kidney Disease

Mar 27, 2025, 7:00 AM EDT - 2 months ago

Regulus Therapeutics Announces Successful Completion of its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of Farabursen (RGLS8429) for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Mar 13, 2025, 4:05 PM EDT - 3 months ago

Regulus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Updates

Mar 4, 2025, 8:00 AM EST - 3 months ago

Regulus Therapeutics to Present at the Leerink Partners 2025 Global Healthcare Conference

Feb 4, 2025, 8:00 AM EST - 4 months ago

Regulus Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 29, 2025, 7:00 AM EST - 4 months ago

Regulus Therapeutics Announces Positive Clinical and Regulatory Updates from its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program for Farabursen (RGLS8429)

Nov 26, 2024, 8:00 AM EST - 6 months ago

Regulus Therapeutics Announces Participation at Upcoming Healthcare Investment Conferences

Nov 7, 2024, 4:05 PM EST - 7 months ago

Regulus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Updates

Oct 8, 2024, 8:00 AM EDT - 8 months ago

Regulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Aug 28, 2024, 8:00 AM EDT - 10 months ago

Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences

Aug 8, 2024, 4:05 PM EDT - 10 months ago

Regulus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Updates

Aug 6, 2024, 8:00 AM EDT - 10 months ago

Regulus Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference

Jun 24, 2024, 7:00 AM EDT - 1 year ago

Regulus Therapeutics Announces Positive Topline Data from the Third Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Jun 4, 2024, 8:00 AM EDT - 1 year ago

Regulus Therapeutics Announces Expected Addition to the Russell 3000® and Russell 2000® Indexes

May 16, 2024, 8:00 AM EDT - 1 year ago

Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical Officer

May 9, 2024, 4:05 PM EDT - 1 year ago

Regulus Therapeutics Reports First Quarter 2024 Financial Results and Recent Updates

May 6, 2024, 8:00 AM EDT - 1 year ago

Regulus Therapeutics Advances to Cohort 4 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Apr 30, 2024, 8:00 AM EDT - 1 year ago

Regulus Therapeutics to Participate in the Canaccord Genuity Genetic Medicine for Generalists Webcast Series

Apr 10, 2024, 12:51 PM EDT - 1 year ago

Regulus: It Is Finding Its Stride Despite Initial Setback In Targeting ADPKD

Mar 21, 2024, 4:05 PM EDT - 1 year ago

Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates

Mar 12, 2024, 6:32 AM EDT - 1 year ago

Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement of Equity

Mar 12, 2024, 6:30 AM EDT - 1 year ago

Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Jan 2, 2024, 4:05 PM EST - 1 year ago

Regulus Therapeutics Announces Completion of Enrollment in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Nov 22, 2023, 8:00 AM EST - 1 year ago

Regulus Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference

Nov 9, 2023, 4:05 PM EST - 1 year ago

Regulus Therapeutics Reports Third Quarter 2023 Financial Results and Recent Updates

Nov 2, 2023, 8:00 AM EDT - 1 year ago

Regulus Therapeutics Announces First Patient Dosed in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Oct 19, 2023, 8:00 AM EDT - 1 year ago

Regulus Therapeutics Advances to Cohort 3 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Sep 20, 2023, 7:00 AM EDT - 1 year ago

Regulus Therapeutics Announces Positive Topline Data from the First Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Sep 13, 2023, 8:00 AM EDT - 1 year ago

Regulus Therapeutics Announces Completion of Enrollment in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Aug 23, 2023, 8:00 AM EDT - 1 year ago

Regulus Therapeutics to Host Virtual Investor Event on September 6, 2023

Aug 8, 2023, 4:05 PM EDT - 1 year ago

Regulus Therapeutics Reports Second Quarter 2023 Financial Results and Recent Updates

Aug 2, 2023, 8:00 AM EDT - 2 years ago

Regulus Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference

Jul 18, 2023, 8:00 AM EDT - 2 years ago

Regulus Therapeutics to Present at the H.C. Wainwright 2nd Annual Kidney Conference

Jun 27, 2023, 8:00 AM EDT - 2 years ago

Regulus Therapeutics Announces First Patient Dosed in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Jun 23, 2023, 8:00 AM EDT - 2 years ago

Regulus Therapeutics Announces Appointment of Preston S. Klassen, M.D.

Jun 20, 2023, 8:00 AM EDT - 2 years ago

Regulus Therapeutics Announces Update on Preclinical Studies in Amyotrophic Lateral Sclerosis in Collaboration with Researchers from Harvard's Brigham and Women's Hospital

Jun 12, 2023, 8:00 AM EDT - 2 years ago

Regulus Therapeutics Strengthens Research & Development Leadership

May 16, 2023, 8:00 AM EDT - 2 years ago

Regulus Therapeutics Advances to Cohort 2 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)